Metabolic
Mazdutide / Survodutide
Dual GLP-1/glucagon agonists · GLP-1/glucagon · dual agonist
Two separate, newer dual-pathway weight-regulation drugs from different developers — both still investigational, grouped here because the community usually discusses them together.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
Mazdutide and survodutide are distinct drugs from different companies, both targeting GLP-1 and glucagon receptors together (a different combination than tirzepatide's GIP/GLP-1 approach). Early trial data for both has shown meaningful weight loss alongside potential liver-fat benefits from the glucagon-pathway component.
Neither is an approved medicine anywhere as of writing. We cover them together because they represent the same emerging 'next generation' category the community talks about in the same breath as retatrutide and CagriSema.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Produces significant weight loss”
Supported by early-to-mid-stage trial data for both compounds; full phase-3 and approval data are still pending.
Claim-level citation mapping is in progress.
“Improves liver fat via the glucagon pathway”
A genuine and actively studied mechanism for this drug class, with some early positive signals.
Claim-level citation mapping is in progress.
“Interchangeable, ready-to-buy alternatives to tirzepatide”
Neither is approved or available through any legal prescription route yet.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Neither drug is approved anywhere yet — both remain in clinical trials. No legal prescription route exists for either; anything sold commercially under these names is an unregulated research chemical.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
Early-stage buzz similar to retatrutide's, from a community that closely follows every new GLP-1-adjacent trial readout. Most discussion correctly notes these are years from potential approval.
Where they’re talking
- News & socialTrial-readout headlines drive periodic spikes in interest.
- r/PeptidesUsually discussed alongside retatrutide as 'the next wave'.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency